Investigational therapies currently in Phase II clinical trials for the treatment of pelvic serous carcinomas

Alice Bergamini, Umberto Leone Roberti Maggiore, Simone Ferrero, Emanuela Rabaiotti, Riccardo Viganò, Micaela Petrone, Patrizia De Marzi, Stefano Salvatore, Massimo Candiani, Giorgia Mangili

Research output: Contribution to journalArticlepeer-review


Introduction: Pelvic serous carcinomas (PSCs) are a controversial entity, which mostly comprise fallopian tube carcinoma (FTC), primary peritoneal carcinoma (PPC) and serous ovarian carcinoma (OC). Despite incremental attention towards understanding pelvic serous carcinogenesis, the gold standard treatment and survival rates have not substantially changed in these last decades.Areas covered: This review summarizes and gives a critical overview of the ongoing Phase II trials investigating therapies for PSC.Expert opinion: Several novel molecules have been developed and are currently under investigation for the treatment of PSC, including FTC, PPC and serous OC. The trend of novel targeted agents is one towards individualized, tailored therapy, based on the molecular and biological differences that characterize tumors that seem similar based solely on histological analysis. The task of developing new molecules is particularly difficult for PSC, given the recurrent development of new patterns of drug resistance. However, even if current research is focused towards identifying the best treatments for each woman with a molecularly defined disease, a deeper knowledge of the molecular biology and genetics underlying FTC and its relation as a precursor of PSC is needed.

Original languageEnglish
Pages (from-to)345-362
Number of pages18
JournalExpert Opinion on Investigational Drugs
Issue number3
Publication statusPublished - 2015


  • Clinical trials
  • Epithelial ovarian cancer
  • Fallopian tube carcinoma
  • Phase II
  • Therapies

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Medicine(all)


Dive into the research topics of 'Investigational therapies currently in Phase II clinical trials for the treatment of pelvic serous carcinomas'. Together they form a unique fingerprint.

Cite this